Ventilator Associated Pneumonia
Conditions
Brief summary
The study has been conducted to measure the clinical outcome of early intervention with colistin inhalation in patients with ventilator associated pneumonia suspected to have multidrug resistant gram -ve bacteria
Interventions
DRUGColistin
Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria.
DRUGCarbapenem + Aminoglycoside/ Quinolone
Dual antipseudomonal given as IV for ventilator associated pneumonia for patients with Multi-drug resistant bacteria risk factors
Sponsors
Ain Shams University
Nourhan Hassan Osama Thuraya Mohamed
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 years Patients presenting with signs of infection 48 hours of intubation
Exclusion criteria
* Patients with documented bronchiectasis Cystic fibrosis Known allergy to polymyxin. Patients presenting with chest infection or signs of infection before intubation. Patients with creatinine clearance less than 30ml/min.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of Ventilatory status | 7 to 10 days | Pf ratio measurement |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Days of mechanical ventilation | 35 Days | Deescalation in the ventilation mode and trials until successful weaning. |
| Time till the occurence of sepsis | 35 Days | long standing ventilator associated pneumonia with failure of treatment can lead to sepsis |
| Mortality as an outcome of long stand untreatable ventilator associated pneumonia | 35 days | is the mortality due to sepsis of other causes |
| Length of stay in the icu | 35 days | How long will the patient stay in the ICU according to failure of weaning and progression of the disease. |
Outcome results
None listed